Perrigo Company Mergers and Acquisitions Summary

Life Science Company

Perrigo Company has acquired 31 companies, including 7 in the last 5 years. A total of 5 acquisitions came from private equity firms. It has also divested 8 assets.

Perrigo Company’s largest acquisition to date was in 2013, when it acquired Elan for $8.6B. It’s largest disclosed sale occurred in 2017, when it sold TYSABRI to Royalty Pharma for $2.9B. Perrigo Company has acquired in 13 different US states, and 10 countries. The Company’s most targeted sectors include medical products (34%) and consumer products (20%).

Join Mergr and gain access to Perrigo Company’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

M&A Summary

  • M&A Total Activity38
    • M&A Buy Activity30
    • M&A Sell Activity8
  • Total Sectors Invested 8
  • Total Countries Invested 10
  • M&A Buy/Sell Connections 20
  • M&A Advisors 10

Perrigo Company PLC

The Sharp Building Hogan Place,
Dublin 2,
Ireland,
+353 1 709 4000
www.perrigo.com

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo Company was founded in 1887 and is based in Dublin, Ireland.


M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (0.8/yr) # 26 - - 2 2 - 30
vol $16.0B $750M $113M $16.9B
Sell (1.4/yr) # 1 4 - 1 1 1 8
vol $2.9B $185M $1.6B $4.6B
  38

Most Recent M&A

Company Date Value Type
Perrigo Company PLC - Prescription Pharmaceuticals Business (Rx) 2021-03-01 1.6B USD Divestiture
Dublin, Ireland
Sanofi SA - OTC Self-Care Brands 2020-08-11 - Divestiture
Paris, France
Rosemont Pharmaceuticals Ltd. 2020-06-01 - Divestiture
Leeds, United Kingdom · www.rosemontpharma.com
High Ridge Brands Co. - Oral Care Assets 2020-02-24 113M USD Divestiture
Stamford, Connecticut
Prevacid 2019-12-02 - Add-on Acquisition
, United States · www.prevacid24hr.com
Perrigo Company PLC - Perrigo Animal Health 2019-07-08 185M USD Divestiture
Dublin, Ireland
Ranir LLC 2019-05-09 750M USD Add-on Acquisition
Grand Rapids, Michigan · www.ranir.com
Omega Bittner 2017-08-15 - Divestiture
Moskva, Russia · www.omega-bittner.ru
Wavelength Pharmaceuticals 2017-08-11 - Divestiture
Petah Tikva, Israel · www.wavelengthpharma.com
TYSABRI (natalizumab) 2017-02-27 2.9B USD Divestiture
, United States · www.tysabri.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 6 (20%) 359M (2%) 6 (75%) 4.4B (96%)
Medical Products 10 (33%) 5.0B (29%) 1 (13%) -
Consumer Products 6 (20%) 970M (6%) 1 (13%) 185M (4%)
Healthcare Services 3 (10%) 8.7B (52%) - -
Food 2 (7%) 1.1B (6%) - -
Chemicals 1 (3%) 48M (< 1%) - -
Consumer Services 1 (3%) 750M (4%) - -
Distribution 1 (3%) - - -
Total 30 $16.9B 8 $4.6B

By Geo

State/Country Buy Value Sell Value
United States 18 3.7B 1 2.9B
  Virginia 2 1.6B - -
  Michigan 2 794M - -
  Pennsylvania 1 160M - -
  New York 1 93M - -
  Nebraska 1 285M - -
  Missouri 1 14M - -
  Minnesota 1 540M - -
  Iowa 1 12M - -
  Georgia 1 36M - -
  Florida 1 49M - -
  Connecticut 1 113M - -
  California 1 - - -
Ireland 1 8.6B 4 1.7B
United Kingdom 4 420M 1 -
Israel 1 - 1 -
Australia 1 48M - -
Belgium 1 4.1B - -
France 1 - - -
Germany 1 - - -
Mauritius 1 51M - -
Mexico 1 25M - -
Russia - - 1 -
Domestic 1 (3%) 8.6B (51%) 4 (50%) 1.7B (38%)
Cross-border 29 (97%) 8.3B (49%) 4 (50%) 2.9B (62%)
Total 30 $16.9B 8 $4.6B

Top M&A Advisors

Financial Deals
J.P. Morgan Securities LLC
3
Houlihan Lokey
1
Barclays Investment Bank
1
Legal Deals
Morgan, Lewis & Bockius LLP
6
Freshfields Bruckhaus Deringer LLP
1
Wachtell, Lipton, Rosen & Katz LLP
1

Deal Values

buy # Total
> $1B 2 $12.7B
$100M to $1B 8 $3.7B
< $100M 12 $515M
TOTAL $16.9B
Largest Elan Corp. plc
$8.6B (2013-12-18)
sell # Total
> $1B 2 $4.4B
$100M to $1B 1 $185M
TOTAL $4.6B
Largest TYSABRI (natalizumab)
$2.9B (2017-02-27)

M&A Connections

Deals
Acquired from
Investor(s)
13%
4 (13%)
Strategic(s)
23%
7 (23%)
Divested to
Investor(s)
38%
3 (38%)
Strategic(s)
63%
5 (63%)

 Subscribe to unlock this and 164,130
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.1K Private Equity Firms
  • 153K M&A Transactions
  • 160K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.2K M&A Advisors
    (Investment Banks and Law Firms)
  • 49K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.